Fármacos antileucotrienos: una nueva expectativa para el control farmacológico de la inflamación en asma

Autores/as

  • Jose A. Arguedas Quesada Universidad de Costa Rica

DOI:

https://doi.org/10.51481/amc.v40i2.585

Palabras clave:

Asma bronquial, Inflamación, Leucotrienos, Fármacos antileucotrienos, Zafirlukast, Montelukast, Pranlukast, Zileuton

Resumen

Esta es una revisión bibliográfica que tiene por objeto analizar las evidencias relacionadas con la efectividad y la seguridad de los agentes antileucotrienos, en los pacientes con asma que pueden beneficiarse de la terapia antiinflamatoria continua.

Los leucotrienos son mediadores endógenos importantes en la patogenia de la respuesta inflamatoria de las vías aéreas. Sus múltiples efectos pueden ser bloqueados con el uso de fármacos que inhiban su síntesis o que antagonicen sus acciones a nivel del receptor.

Con el uso de esos fármacos se consigue disminuir los síntomas del asma, mejorar el FEVi y reducir el uso de Otros medicamentos; su eficacia es moderada. En comparación con otras drogas antiinflamatorias, tienen las ventajas de que se administran por la vía oral y que su acción se inicia rápidamente. En general son bien tolerados, aunque existe preocupación sobre la hepatotoxicidad del zileuton.

Se recomienda su uso como terapia alternativa a los glucocorticoides inhalados en asma leve-moderada, y combinada con glucocorticoides inhalados y broncodilatadores de acción prolongada en asma severa. Se requiere de más estudios clínicos para definir el lugar preciso que estos fármacos ocuparán en el tratamiento ambulatorio crónico del asma bronquial.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997; 111 (Suppl. 2): 27S-34S

Lewis RA,AustenF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human disease. N Eng J Med 1990; 323:645-55.

Kumar A, BusseW. Airway inflammation in asthma. Sci & Medicine 1995; 2:38-47.

Spector SL. Update on exercise-induced asthma. Ann Allergy 1993; 71:571-7.

Di Stefano A, Lusuardi M, Braghiroli A, Donner CF. Nocturnal asthma: mechanisms and therapy. Lung 1997; 175:53-61.

Miller DR', Gillard JW, Vickers PJ, Sadowuki S, Léveillé C, Mancini JA, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343:278-81.

Samuelson B, Dahlen SE, Lindgren JA. Leukotrienes and lipoxins: structures, biosynthesis and biological effects. Science 1987; 237:1171-76.

Smith LJ. Leukotrienes in asthma. The potential role Of antileukotreiene agents. Arch Int Med 1996; 156:2181-9.

Sigal E. The molecular biology of mammalian arachidonic acid metabolism. Am J Physiol 1991; 260:Ll 3-28.

Tudhope BayG9773,anove1antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. EurJ Pharmacol 1994; 264:317-23.

Labat C, Ortiz JL, Norel X, et al. A second cisteinyl leukotriene receptor in human lung. J Pharmacol Exp Ther 1992; 263:800-5.

Martin TR, Pistorese BP, Chi Eh', Godman RB, Matthay MA. Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into alveolar spaces without a change in pulmonary permeability. J Clininvest 1989; 84:1609-19.

Nagy L, Lee TH, Goetzl EJ, et al. Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipooxygenase products. Clin Exp Allergy 1983; 71:394-8.

Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84:2068-2101.

Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994; 121:684-97.

Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997; 17 :3S-12S.

Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288:484-6.

Dahlen SE, Hansson G, Hedqvist P, Bjorck T, Granstrom E, Dahlen B. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlates with the release of leukotriene C4, D4 and E4. Proc NatlAcad sci USA 1983; 80:1712-6.

Jorisl, MajnoG, Corey Ej, Lewis RA. The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction. Am J Pathol 1987; 126:19-24.

Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M. Slow-releasing substances, leukotrienes C4 and D4 increase the release of mucus fron the human airways in vitro.. Am Rev Resp Dis 1982; 126:449-51.

Kaye MG, Smith LJ. Effects of inhaled leukotriene D4 and platelet activating factor on airway reactivity in normal subjects. Am Rev Resp Dis 1990; 141:993-

Arm JR spur BW, Lee TH. The effects of inhaled eukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. J Allergy Clin Immunol 1988; 82:645-60.

Baud L, Pérez J, Denis M, Ardaillou R. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J Immunol 1987; 138:1190

Palmerg L, Claesson HE, Thyberg J. Leukotrienes stimulate initiation of DNA synthesis in cultured arterial smooth muscle. J Cell Sci 1987; 88:151-9.

LeikaufGD, Claesson HE, Doupnik CA, Hybbinette S, Grafstrom RC. Cysteinyl leukotrienes enhance growth of human airway epitheiial cells. AmJ Physiol 1990; 259:L255-61.

Pedersen KE, Bochner BS, Undem BJ. Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a nonCysLTI receptor mediated mechanism. J Pharmacol Exp Ther 1997.

Taylor 1K, Ward ps, Taylor GW, et al. Inhaled PAF stimulates leukotriene and tromboxano A2 production in humans. J Appl Physiol 1991; 71:1496-402.

activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219. Am Rev Resp Dis 1993; 147:215-7.

Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. JAMA 1996; 275:931-6.

Knapp HR, Sladek K, Fitzgerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Invest 1992; 119:48-51.

McGillKA, WW. Zileuton. Lancet 1996; 348:519-24.

Ford-Hutchinson AW. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes. Trends Pharmacol Sci 1991; 12:68-70.

Bell RL, Young PR, Albert D, et al. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Int J Immunopharmacol 1992; 14:505-10.

Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5lipoxygenase inhibitor on asthma induced by cold, dry air. N Eng J Med 1990; 323:1740-4.

FischerAR, McFadden CA, Frantz R,Awni WM, Cohn S, Drazen JM, et al. Effect of chronic 5-lipoxygenase inhibition on airway hiperresponsiveness in asthmatics subjects. Am J Respir Crit Care Med 1995; 152:1203-7.

Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise induced bronchospasm by zileuton: a 5-lypoxygenase inhibitor. Am J Resp Crit Care Med 1996.

Spector S, Miller CJ, Glass M. 13 week dose-response study with Accolate( (zafirlukast) in patients with mild-to-moderate asthma (abstract). Am J Respir Crit Care Med 1995; 151 :A379.

LockeyRF, Lavins BJ, SnaderL. Effects of 13 weeks oftreatment with ICI 204,219 (Accolate() in patients with mild-to-moderate asthma (abstract). J Allergy Clin Immunol 1995; 95:350.

Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997; 52:523-7.

Reiss T, Altman LC, Chervinsky P, BewtraA, Stricker WE, Noonan GP, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98:528-34.

Reiss TF, Sorkness CA, Stricker W, BottoA, BusseWW, Kundu S, et al. Effects of montelukast (MK 0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52:45-8.

Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337:1062-3.

Suissa S; Dennis R; Emst P; Sheehy O; Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mildto-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126:177-83.

Holgate ST, Anderson KD, Rodgers EM. Comparison of "Accolate" (zafirlukast) with sodium cromoglicate in mild to moderate asthmatic patients (abstract). Allergy 1995; 50:319-20.

Nathan RA, Glass M, SnaderL. Effects of 13 weeks treatment with ICI 204,219 ("Accolate") or cromolyn sodium ("Intal") in patients with mild to moderate asthma (abstract). J Allergy Clin Immunol 1995; 95:388.

Krell RD, Aharony D, BucknerCK, Keith RA, KusnerEJ, Snyder DW, et al. The preclinical pharmacologyof ICI 204,219, a peptide leukotriene antagonist. Am Rev Resp Dis 1990;

Anonymous. Zafirlukast approved for asthma. Med Sci Bull 1996, 38:11-2.

Cheng H, LeffA, Amin R, Gertz BJ, Demet M, Noonan N, et al. Pharmacokinetics, bioavailability and safety Of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996; 13•.445-8.

Brocks DR, Upward JW, Georgiou P, Stelman G, Doyle E, Allen E, et al, ,The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers. Eur J Clin Pharmacol 1996; 51:303-8.

Grossman J, Faiferman I, Dubb JW, Thompson DJ, Busse W, Bronsky E, et al. Results of the first U.S. double-blind, placebocontrolled, multicenter clinical study in asthma with Pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997; 34:321-8.

Tamaoki J, Kondo M, Sakai N, Nakata J, Takemura H, Nagni A, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo JoshiIdai Asthma Research Group. Am J Respir Crit Care Med 1997; 155:1235-40.

Kelloway JS, Wyatt RA, Adlis SA. Comparison of patientsf compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154:1349-53.

Jain P, Golish JA. Clinical management of asthma in the 1990's. Current therapy and new directions. Drugs 1996; 52 (Suppl.6): 1-11.

NIH Expert Panel Report Il Guidelines. NIH Publication 97-405, 1997.

Barnes PJ. Inhaled glucocorticoids for asthma. N Eng J Med 1995; 332:868-75.

Descargas

Publicado

1998-06-01

Cómo citar

Arguedas Quesada, J. A. (1998). Fármacos antileucotrienos: una nueva expectativa para el control farmacológico de la inflamación en asma. Acta Médica Costarricense, 40(2), 5–13. https://doi.org/10.51481/amc.v40i2.585